Another phase 2 trial is testing Zenocutuzumab in combination with chemotherapy, trastuzumab, and endocrine therapy for HER2-low and estrogen receptor-positive breast cancers, respectively (NCT03321981). The gene discussed is ERBB2; the disease is breast carcinoma.